This narrative review aims to be a resource for all clinicians prescribing ASMs so that they can create a welcoming environment to enable successful treatment of seizures and reduce the risk of HIV infection in people at risk. In addition, we highlight knowledge gaps ...
It has not been possible thus far to assess the efficacy and outcome of HIV PEP in our clinic. This is because most of our patients did not return for follow up visits. There is therefore an urgent need by the various counseling units to institute an efficient and strict contact tracing ...
HIV+ patients still need PCP prophylaxis 来自 EBSCO 喜欢 0 阅读量: 32 作者: CA Kemper 摘要: The article reports that prophylaxis against pneumocystic carinii pneumonia (PCP) remains the single most cost-effective intervention in HIV+ patients at risk. 年份: 2007 ...
patients with a negative HIV test result. Such stringent conditions, however, would reduce access. The FDA instead required the manufacturer of emtricitabine/tenofovir to train and educate health care professionals and collect drug utilization data. The FDA labeling recommends HIV testing at least ...
Original Investigation Preexposure Prophylaxis for HIV Infection Albert Y. Liu, MD, MPH; Stephanie E. Cohen, MD, MPH; Eric Vittinghoff, PhD; Peter L. Anderson, PharmD; Susanne Doblecki-Lewis, MD; Oliver Bacon, MD, MPH; Wairimu Chege, MD, MPH; Brian S. Postle, BS; Tim Ma...
A 2-month course of therapy to prevent active tuberculosis in patients infected with the human immunodeficiency virus (HIV) is an effective alternative to the 12-month regimen currently recommended for people coinfected with HIV and tuberculosis (TB), according to a study of nearly 1600 patients ...
Background Recently, a number of antibodies capable of broadly neutralizing HIV have been isolated from HIV infected patients, stimulating efforts to develop vaccines capable of eliciting their production in naive individuals. As an alternative to vaccination, we recently described vectored immunoprophylaxi...
(TDF/FTC) is used for PrEP and in HIV treatment alike without the possibility to distinguish its use in the prescription data. To determine the number of defined daily doses (DDD) used for PrEP, we set as baseline the number of DDD prescribed for HIV treatment during the first two ...
These are factors that clinicians and patients can consider as they discuss the use of PrEP for HIV prevention. In addition, risk behaviors should be interpreted in the context of the HIV prevalence in a community or network; that is, risk behaviors in a high-prevalence setting carry a ...